Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02890368 · ClinicalTrials.gov registry record · Phase 1
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT02890368 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 56 participants.
The verdict
NCT02890368, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts. Part 1 is the Dose Escalation phase and Part 2 is the Dose Expansion phase. The purpose of this study is to characterize the safety profile of TTI-621 and to determine the optimal dose and delivery schedule of TTI-621. In addition, the safety and antitumor activity of TTI-621 will be evaluated in combination with other anti-cancer agents or radiation.
Interventions
- DRUG TTI-621 Monotherapy
- DRUG TTI-621 + PD-1/PD-L1 Inhibitor
- DRUG TTI-621 + pegylated interferon-α2a
- OTHER TTI-621 + T-Vec
- OTHER TTI-621 + radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2016-09 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02890368
The ClinicalTrials.gov registry entry for NCT02890368 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which TTI-621 Monotherapy is the first listed.
NCT02890368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02890368 about?
NCT02890368 is a clinical study titled "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides". This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts. Part 1 is the Dose Escalation phase an...
What is the current status of trial NCT02890368?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2016-09. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT02890368?
The interventions under investigation include: TTI-621 Monotherapy (DRUG), TTI-621 + PD-1/PD-L1 Inhibitor (DRUG), TTI-621 + pegylated interferon-α2a (DRUG), TTI-621 + T-Vec (OTHER), TTI-621 + radiation (OTHER).
Who is sponsoring clinical trial NCT02890368?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.